论文部分内容阅读
[目的]探讨脑恶性肿瘤缺失基因1(DMBT1)在肾癌组织中的表达及其意义。[方法]采用免疫组织化学方法检测47例肾癌组织及距其癌组织边缘2cm以上的镜下未见癌浸润的正常组织中DMBT1蛋白表达情况。[结果]免疫组织化学结果表明,DMBT1蛋白在肾癌组织及正常肾脏组织中的表达阳性率分别为31.9%、76.6%,差异有统计学意义(P<0.05)。DMBT1蛋白表达与肾癌患者性别、年龄、肿瘤大小无关(P>0.05);而与细胞分化程度、淋巴结转移以及肿瘤临床分期有关(P<0.05)。Kaplan-Meier生存分析提示,DMBT1表达阳性的肾癌患者5年总生存率明显高于表达阴性者,差异具有统计学意义(P<0.05)。[结论]肾癌组织中DMBT1蛋白表达降低,且与肾癌细胞分化程度、淋巴结转移、临床分期及患者预后有关。
[Objective] To investigate the expression of DMBT1 in renal cell carcinoma and its significance. [Method] Immunohistochemical method was used to detect the expression of DMBT1 protein in 47 cases of renal cell carcinoma and normal tissue with no carcinoma infiltration more than 2cm away from the edge of the cancer tissue. [Results] Immunohistochemistry results showed that the positive rates of DMBT1 protein expression in renal cell carcinoma and normal kidney tissues were 31.9% and 76.6%, respectively, with statistical significance (P <0.05). The expression of DMBT1 protein was not related to the gender, age and tumor size of patients with renal cell carcinoma (P> 0.05), but correlated with cell differentiation, lymph node metastasis and clinical staging (P <0.05). Kaplan-Meier survival analysis showed that the 5-year overall survival rate of patients with DMBT1 positive renal cell carcinoma was significantly higher than that of negative expression, the difference was statistically significant (P <0.05). [Conclusion] The expression of DMBT1 protein in renal cell carcinoma is decreased, which is related to the differentiation of renal cell carcinoma, lymph node metastasis, clinical stage and prognosis.